BiotechTV - News
BiotechTV
This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.
Episodes
Mentioned books
Jul 23, 2025 • 10min
NYSE Strategist Eric Criscuolo shares his take on the markets and biotech sentiment
He discusses the importance of interest rates to high risk sectors like biotech, and comment on how our sector has not performed lately like other "risk-on" assets have. Plus, explaining his job of helping CEOs of NYSE listed companies understand the economic and capital markets environment.Note: The NYSE is a sponsor of BiotechTV
Jul 22, 2025 • 13min
AI x Bio Summit: The Co-Founder and Head of Machine Learning at Dyno Therapeutics describes how his company is using AI to design better capsids
Sam Sinai talks about how capsids are being more precisely designed today, which is allowing drug developers to better target them to different organs and to improve their efficiency. Plus, why he believes AI will help make cell and gene therapies reach more patients in the future.
Jul 22, 2025 • 10min
RBC's Healthcare Desk Strategist Chris McCarthy discusses biotech sentiment, and positioning around key events and catalysts that are upcoming
He highlights recent M&A, but also notes how the sector has not been reliant on deals like it has in the past. Plus, discussing how Sarepta's wild ride has not led to contagion, and previewing what key data events are upcoming.
Jul 22, 2025 • 11min
AI x Bio Summit: Nimbus Therapeutics' new CEO and head of R&D describe how AI is an isn't used in the company's R&D process
CEO Abbas Kazimi and President of R&D Peter Tummino discuss how AI integrates into their discovery and clinical development work, and walk us through some of the company's current programs.
Jul 22, 2025 • 18min
Metsera CEO Whit Bernard shares an update on the company's obesity programs, and comments on the state of the field post ADA
He describes data that Mestera presented at ADA for its monthly-dosed GLP1 and also its amylin analog. Plus, recent learnings about the field in general, including what orforglipron might mean for the oral therapy space and why Metsera believes in an oral peptide.
Jul 22, 2025 • 12min
Cambridge, MA based Avalyn Pharma is developing a novel inhaled formulation of pirfenidone and other medicines for pulmonary fibrosis - it just raised a $100M (up round) series D financing
CEO Lyn Baranowski describes the therapy and demonstrates the nebulizer that delivers it, and explains how Avalyn's method is designed increase the dose patients can take vs oral therapies and, therefore, increase the therapeutic value.
Jul 21, 2025 • 9min
On a visit through London today, NodThera's CEO Dan Swisher discusses the company's brain-penetrant NLRP3 platform, including an asset that's in phase 2 for weight loss
He discusses the science behind NLRP3, and describes why he thinks NodThera's brain penetration differentiates it from other programs from pharma and other companies. The weight loss program is a oral therapy that doesn't require titration and hasn't shown GI tolerability side effects.
Jul 17, 2025 • 25min
Prime Medicine's new CEO Allan Reine walks us through the prime editing company's new focused pipeline
He describes the benefits of prime editing, walks us through human proof-of-concept data that was announced in a patient with Chronic Granulomatous Disease, and explains the rationale to focus on Wilson's Disease, Alpha-1 Antitrypsin Deficiency, Cystic Fibrosis, and the company's CAR-T partnership with Bristol Myers Squibb.
Jul 16, 2025 • 31min
Kailera Therapeutics' partner Hengrui announced positive p3 results for its GLP1/GIP agonist in China - biotech veteran and Kailera CEO Ron Renaud walks us through the company's obesity space strategy
He describes why Kailera chose to in-license a GLP1/GIP specifically, and describes where he sees this asset placing in the competitive landscape based on this data. Plus, commentary on CMC, business development, oral therapies, and more.
Jul 16, 2025 • 12min
Southampton professor, and Curve Therapeutics' CSO, Ali Tavassoli describes the unique properties of cyclic peptides and why he believes Curve's cell-based method to drug discovery makes it different
He describes the properties that make cyclic peptides unique compared to small molecules and antibodies, and how Curve's approach is different than others in the field. Plus, the work his team is doing on cyclic peptides in their lab at University of Southampton.
